PAC1R antagonist 1
CAS No. 2305204-24-2
PAC1R antagonist 1( —— )
Catalog No. M37140 CAS No. 2305204-24-2
PAC1R antagonist 1 is an orally active PAC1 receptor antagonist that inhibits abnormal pain induced by pituitary adenylate cyclase-activating polypeptide (PACAP) and nerve damage, and may be used in the study of neoplasms and immune-related disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 226 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePAC1R antagonist 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionPAC1R antagonist 1 is an orally active PAC1 receptor antagonist that inhibits abnormal pain induced by pituitary adenylate cyclase-activating polypeptide (PACAP) and nerve damage, and may be used in the study of neoplasms and immune-related disorders.
-
DescriptionPAC1R antagonist 1 (compound 3d) is a potent and orally active antagonist of PAC1 receptor. PAC1R antagonist 1 can inhibit pituitary adenylate cyclase-activating polypeptide (PACAP)- and nerve injury-induced allodynia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorPACAP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2305204-24-2
-
Formula Weight372.81
-
Molecular FormulaC17H17ClN6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 33.33 mg/mL (89.40 mM; ultrasonic and warming and heat to 160°C )
-
SMILESO=C(NCCC1=CN=CN1)C2CC(=O)N(C3=NNC=4C(Cl)=CC=CC34)C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Takasaki I, et, al. Synthesis of a novel and potent small-molecule antagonist of PAC1 receptor for the treatment of neuropathic pain. Eur J Med Chem. 2020 Jan 15;186:111902. ?
molnova catalog
related products
-
Thalidomide-O-amido-...
Thalidomide-O-amido-C6-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker.
-
Semustine
Semustine, a DNA alkylating agent, is a cancer chemotherapy compound that is nephrotoxic in patients with malignant melanoma receiving adjuvant chemotherapy for the adjuvant treatment of leukemia.
-
Lucerastat
A galactose analogue that is an UDP-glucose ceramide glucosyltransferase (UGCG/GCS) inhibitor (IC50=41.4 uM).
Cart
sales@molnova.com